Valued at a market cap of $27.5 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical gadget firm that focuses on the design, growth, and commercialization of steady glucose monitoring (CGM) programs for the administration of diabetes and metabolic well being in the USA and internationally.
DXCM is predicted to launch its Q2 2026 earnings quickly. Forward of the occasion, analysts anticipate the corporate’s EPS to be $0.61 on a diluted foundation, up 27.1% from $0.48 within the year-ago quarter. The corporate has exceeded Wall Avenue’s EPS estimates in every of its final 4 quarters.
Extra Information from Barchart
For fiscal 2026, analysts venture the corporate’s EPS to be $2.57, up 23% from $2.09 in fiscal 2025. Furthermore, its EPS is predicted to rise by roughly 18.7% 12 months over 12 months (YoY) to $3.05 in fiscal 2027.
DXCM inventory has declined 14.8% over the previous 52 weeks, lagging behind the S&P 500 Index’s ($SPX) 19.2% rise and the State Avenue Healthcare Choose Sector SPDR ETF’s (XLV) 21% rise throughout the identical timeframe.
On Apr. 30, DXCM inventory rose 3.5% following the discharge of its Q1 2026 earnings. The corporate’s income for the quarter amounted to $1.2 billion and surpassed the Avenue’s estimates. Furthermore, its adjusted EPS for the interval got here in at $0.56, additionally topping Wall Avenue’s forecasts. DexCom expects full-year income within the vary of $5.16 billion to $5.25 billion.
Analysts are extremely optimistic about DXCM, with the inventory having a “Sturdy Purchase” ranking total. Among the many 28 analysts masking the inventory, 23 are recommending a “Sturdy Purchase,” one suggests a “Average Purchase,” three advocate a “Maintain,” and one suggests a “Sturdy Promote.” DXCM’s common analyst worth goal is $83.65, indicating an upside of 17.4% from the present ranges.
On the date of publication, Aritra Gangopadhyay didn’t have (both instantly or not directly) positions in any of the securities talked about on this article. All info and information on this article is solely for informational functions. This text was initially printed on Barchart.com